| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABT | Common shares without par value | Award | $0 | +13,677 | +21% | $0.000000 | 78,704 | 21 Feb 2024 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABT | Option (right to buy) | Award | $0 | +51,397 | $0.000000 | 51,397 | 21 Feb 2024 | Common Shares | 51,397 | $116.98 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. |
| F2 | Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 17,132 on February 21, 2025, 17,132 on February 21, 2026, and 17,133 on February 21, 2027. |